{
    "id": "correct_subsidiary_00046_0",
    "rank": 91,
    "data": {
        "url": "https://virtici.com/leadership",
        "read_more_link": "",
        "language": "en",
        "title": "Leadership",
        "top_image": "https://virtici.com/templates/theme3715/images/favicon.ico",
        "meta_img": "https://virtici.com/templates/theme3715/images/favicon.ico",
        "images": [
            "https://virtici.com/images/logo1.png",
            "https://virtici.com/images/team/neil-white.jpg",
            "https://virtici.com/images/jake-white.jpg",
            "https://virtici.com/images/team/gary-white.jpg",
            "https://virtici.com/images/team/jooe2-headshot.jpg",
            "https://virtici.com/images/logo1.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "/templates/theme3715/images/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://virtici.com/leadership",
        "text": "Dr. Fanger has over 20 years of experience in the life sciences industry, spanning business development, product strategy, and biological research. Previously, he co-founded Teranode Corporation (acquired by Rage Frameworks, Inc., which was acquired by Genpac (NYSE:G)), where he led teams that introduced new AI and software automation products into the marketplace. He was responsible for securing worldwide partnerships with strategic customers such as Daiichi Sankyo, Grünenthal GmbH, Pfizer, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. Prior, Dr. Fanger held scientist positions at Corixa Corporation (acquired by GSK) and Immunex Corporation (acquired by Amgen). Dr. Fanger serves as the Chairman of Rise Therapeutics and a scientific director of Celdara and MBV. He is co-inventor on several patents covering novel biological therapeutics and software technologies, and co-author on numerous research publications in leading scientific journals. Dr. Fanger graduated from Denison University with a BS in chemistry and Dartmouth Medical School with a PhD in physiology.\n\nDr. Reder is currently CEO of Celdara Medical, LLC. Dr. Reder previously founded the New Ventures Office at Dartmouth Medical School and still serves as its first Director. Prior to Dartmouth, he led new business platforms and projects, external innovation, and knowledge management initiatives at Cabot Corporation. He started up Cabot’s Printed Electronics Business and Optical Composites Platform, and was a member of Cabot’s Research Council, Technology Board, and Nanotechnology EHS Council. He joined Cabot’s New Business Development team from PolyTechnos Venture-Partners, a Munich-based venture capital firm where he conducted due diligence and advised on early-stage technology investments. He serves on the Boards of the New Hampshire Academy of Science, Virtici, and MBV, and is Chairman of CairnSurgical, and Javelin Oncology. Jake has lived, studied and worked in Canada, Germany, and the USA, with experiences in research, venture investing, corporate alliances and internal startups, academia, and startups. He earned a BSc with First Class Honors from the University of Waterloo, and a PhD in Chemistry as a Brown-Wetherill Fellow at Purdue University and Ludwig Maximilians Universität.\n\nDr. Fanger is currently co-founder and CEO of Rise Therapeutics. His extensive career has been in the biotechnology industry, developing novel therapeutics, establishing drug development alliances, and leading M&A activities. He serves as a director on the boards of Virtici and OncoImmune. In his previous role as Senior Vice President & Chief Operating Officer at Amplimmune, Dr. Fanger helped to lead the $500 million acquisition by Medimmune/AstraZeneca in 2013. Prior to joining Amplimmune, Dr. Fanger was Vice President of Business Development at MacroGenics where he directed partnering activities that included establishing MacroGenics’ strategic alliance with Eli Lilly & Company. Before MacroGenics, Dr. Fanger was responsible for a diverse array of corporate functions at Corixa Corporation, including heading up business development activities, establishing and directing the therapeutic antibody development program, and managing numerous pharma strategic alliances. Dr. Fanger has co-authored over 45 articles, book chapters and reviews in peer-reviewed journals in the areas of monoclonal antibody development, cell biology, and cancer research. He has also been awarded 35 patents. Dr. Fanger received his MBA from Seattle University, PhD in Molecular and Cellular Biology from Dartmouth Medical School, and his BS in Chemistry from Denison University.​ ​\n\nDr. Trebley is currently co-founder and CEO of Monon Bioventures (MBV). Prior to MBV, he was the Head of Startups at the Indiana University Research and Technology Corporation. He was responsible for assisting Indiana University faculty, staff, and students form and run more than 25 startup companies. Specifically, he assisted with university inventors to form a new entity and find initial funding through early-stage resources like the SBIR/STTR programs, angel investment, corporate partners and venture capital. The program’s success and popularity with top scientists and physicians inspired the formation of Monon Bioventures. Dr. Trebley also served in technology transfer at the Purdue Research Foundation managing a wide range of portfolios in the medical device, software, pharmaceutical, agriculture, and chemical disciplines. Previously, he worked as a Principle within the venture capital group In-Vivo Ventures and served as Vice President of Research and Development for Kylin Therapeutics. Dr. Trebley has a BS in Chemistry from Wabash College and a PhD in Medicinal Chemistry and Molecular Pharmacology from Purdue University. ​"
    }
}